AstraZeneca: Data at CHEST 2026 Provide Further Evidence Supporting the Favorable Clinical Profile of Tozorakimab in COPD
October 14, 2026
October 14, 2026
WILMINGTON, Delaware, Oct. 14 -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
New data at CHEST 2026 provide further evidence supporting the favorable clinical profile of tozorakimab in COPD
12 October 2026
Key analyses from the positive Phase III OBERON and TITANIA trials and results from the PROSPERO long-term extension trial reinforce tozorakimab's broad and durable benefits in patients with chronic . . .
* * *
New data at CHEST 2026 provide further evidence supporting the favorable clinical profile of tozorakimab in COPD
12 October 2026
Key analyses from the positive Phase III OBERON and TITANIA trials and results from the PROSPERO long-term extension trial reinforce tozorakimab's broad and durable benefits in patients with chronic . . .